Company intelligence / Profile preview

Shanghai Junshi Biosciences Co., Ltd.

Shanghai, Shanghai, Chinajunshipharma.com ↗

Ownership: Public · 1877.HK
Employees: ~2500
Development stage: Commercial

Overview

Four drugs have been commercialized, around 30 assets are undergoing clinical trials, and over 20 drug candidates are at the preclinical drug development stage

Therapeutic areas: Metabolic DisordersImmunologyOncologyNeurologyInfectious Diseases
Modalities: Monoclonal antibodiessmall molecule drugspolypeptide drugsantibody drug conjugates (ADCs)bi-specific or multi-specific antibodiesbispecific antibody drug conjugatesfusion proteinnucleic acid drugs
Industry: Biotech

Drug pipeline

56 assets

tifcemalimab

55 more assets in the full pipeline.

Request access →

Partnerships

Coherus BioSciences (for toripalimab in the US and Canada)Rxilient Biotech (joint venture for Southeast Asian markets)

Beyond the preview

Go deeper on Shanghai Junshi Biosciences Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Junshi Biosciences Co., Ltd..

Explore the full profile